In-vitro Activity of Ceftolozane-Tazobactam Against Multi-Drug Resistant<i>Pseudomonas aeruginosa</i> in a Tertiary Care Center in Al-Ahsa, KSA

Abstract Introduction/Objective Pseudomonas aeruginosa is a major nosocomial pathogen often causing serious multi-drug resistant (MDR) infections. Resistant strains, including carbapenem-resistant (CR), are increrasing especially in intensive care units (ICU) which limits treatment options to nephrotoxic aminoglycosides and polymyxins, results failure of initial therapy, significant mortality, morbidity cost. Ceftolozane-tazobactam (CT) novel antimicrobial showing good activity against MDR CR isolates; however, reports resistance increasing. Data from KSA scarce. The aim this study determine the in-vitro CT P. Methods/Case Report Single-center retrospective observational patients with infection 2020 2021. susceptibility anti-pseudomonal drugs were retreived medical records. Non-duplicate consecutive first isolates all clinical specimens included. strains labeled following international guidelines. was analyzed using Statistical Package for Social Sciences software (SPSS®). Results (if Case Study enter NA) Out 538 collected, 98 (18.2%) 62 (11.5%) MDR. mainly retrieved respiratory samples (44%), bedsores (29%) urine (21%). 62% 76% &amp;gt;60 years age; significantly higher than younger patients. 85% (83/98) 81% (50/62) came ICU where prevalence 34% 20%, respectively; other areas. Overall sensitivity 97%, 71% isolates. Only amikacin performed better 98% overall, 92% 86% Sensitivity 94%. effective 83% 70% second only (90% 84%, respectively). Other tested antimicrobials ineffective Conclusion shows It may provide therapeutic option treat urinary tract infections hospital-acquired or ventilator-associated pneumoniae critically ill elderly More studies on responses emergence required establish role as an